Featured Courses

Rare Adverse Events of Immune Checkpoint Inhibitor Therapy | myCME

CNE Contact Hour(s)

This activity is designed to provide oncology nurses with an enhanced understanding of the mechanisms of immune-related adverse events (irAEs), awareness of rarer irAEs and strategies for collaboratively managing irAEs using a patient centered approach.

Targeted Treatments for Urothelial Cancer

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AANP Contact Hour(s)

This activity will help advanced practitioners who treat patients with UC to know how to select and sequence these treatments.

Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

AMA PRA Category 1 Credit(s)^TM

The advent of poly-(ADP ribose)-polymerase (PARP) inhibitors for a variety of malignancies has led to the evaluation of their use in patients with metastatic castrate resistant prostate cancer (mCRPC), and has the potential to shift treatment paradigms for these patients.

1,800 Seconds™ in The Expanding Role of PARP Inhibitors in Ovarian Cancer | myCME

AMA PRA Category 1 Credit(s)^TM

A 30-minute video-based online module designed to provide an overview of current evidence on the expanding role of PARP inhibitors in the treatment of ovarian cancer. Dr. Kathleen Moore presents a patient case to provide context for a discussion of emerging data, ongoing clinical trials, and evidence-based strategies to support appropriate selection of patients for treatment with PARP inhibitors.

Managing Immune-Related Adverse Events in the ED | myCME

AMA PRA Category 1 Credit(s)^TM

This 1.0-hour, CME-certified program, presented by Drs Christopher J. Coyne and Jayne Viets-Upchurch, will review the fundamentals of ICIs as used for cancer treatment, including standard-of-care regimens and the mechanisms of action for these agents. It will also highlight guideline-recommended approaches to recognizing and treating irAEs associated with ICI monotherapies and combination regimens in the ED setting.

Giving Shingles Immunization Your Best Shot: Implementing a Shingles Vaccination Protocol in Your Practice | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

This CME Outfitters Live and OnDemand webcast will focus on the burden imposed by shingles, improving uptake of vaccination and series completion for shingles through patient education, and applying real-world strategies to implement shingles immunization protocols.

Oral Therapy for Outpatient Management of Multiple Myeloma: Options for the COVID-19 Era | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

In this webcast, a panel of renowned clinical MM experts provides timely support and guidance to oncology HCPs on how to respond to the needs of MM patients in the current COVID-19 public health emergency.

Immunotherapy for Multiple Myeloma: From Antibodies to CAR T–Cell Therapy

ANCC Contact Hour(s)

Multiple myeloma remains incurable, but the number and type of treatments continue to expand rapidly. This enduring CNE activity provides information on the newest myeloma immunotherapy treatments, including their rationale for use and results from ongoing clinical studies.

Disparities and Improving the Care of Advanced HCC in the Hispanic Community | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

Significant race and ethnicity-specific disparities in HCC care account in many respects for the increased incidence—approximately 36%—of HCC among Hispanics, who are more likely to present late and less likely to receive any HCC-directed treatment. However, improved screening and surveillance guidelines and greater understanding of the pathophysiology and molecular pathways in HCC has led to the emergence of targeted treatment.

Navigation Strategies for Patients with Breast Cancer | myCME

CNE Contact Hour(s)

This activity will provide ONNs best practices on the successful implementation of the nurse navigator role in the management of newly diagnosed and metastatic breast cancer.

Tenosynovial Giant Cell Tumors: New Treatments for a Distinct and Often Misdiagnosed Disease | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

The current standard of care for localized tenosynovial giant cell tumors (TGCT) is surgical resection. However, diffuse disease often has more extensive involvement and a poorer likelihood of successful cure with surgery, higher risk of recurrence, and substantial morbidity and lower quality of life.

A 35-year-old Woman with Worsening Pain and Swelling in the Knee | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

The current standard of care for localized tenosynovial giant cell tumors (TGCT) is surgical resection; however, diffuse disease often has more extensive involvement and a lower likelihood of a successful cure with surgery, higher risk of recurrence, and substantial morbidity and lower quality of life. These issues come to light for a 35-year-old woman who presents to her primary care physician with worsening pain and swelling in the knee, and is later diagnosed with, and treated for TGCT.